Reboxetine
versus fluoxetine: social functioning
From symptoms to social functioning: differential effects of antidepressant therapy.
Kasper S
Department of General Psychiatry,
University of Vienna, Austria.
Int Clin Psychopharmacol 1999 May; 14 Suppl 1:S27-31
ABSTRACT
Significant impairments in social functioning frequently occur simultaneously with depressive symptoms. The implications of such impairments extend beyond the depressed individual to their family, friends and society at large. Classical rating scales such as the Hamilton rating scale for depression primarily assess the core symptoms of depression. A range of rating scales are available, both self-reporting and administered by clinician; however, many have been criticised for their unspecified conceptual background and for being complex and time-consuming. While antidepressants in general appear to improve social functioning, no clear advantage for any single class of agent has been reported. Recently, a new self-report rating scale, the Social Adaptation Self-evaluation Scale, has been developed and used to compare the novel selective noradrenaline reuptake inhibitor, reboxetine, with the selective serotonin re-uptake inhibitor, fluoxetine.
The noradrenergic agent, reboxetine, was shown to be significantly more effective in improving social functioning than the serotonergic agent,
fluoxetine. These findings are consistent with previous observations that noradrenaline may preferentially improve vigilance, motivation, and self-perception.